

Europäisches Patentamt
European Patent Office
Office européen des brevets



(11) **EP 1 127 883 A2**

(12)

EUROPEAN PATENT APPLICATION

(43) Date of publication:
29.08.2001 Bulletin 2001/35

(21) Application number: 01103521.9

(22) Date of filing: 16.02.2001

(51) Int Cl.7: **C07D 263/32**, C07D 413/12,
C07D 417/12, A61K 31/421,
A61K 31/422, A61K 31/4439,
A61K 31/454, A61P 29/00,
A61P 31/00, A61P 35/00,
A61P 37/00

(84) Designated Contracting States:
**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE TR**
Designated Extension States:
AL LT LV MK RO SI

(30) Priority: 24.02.2000 GB 0004392
28.06.2000 GB 0015877
17.08.2000 GB 0020322

(71) Applicant: **F. HOFFMANN-LA ROCHE AG**
4070 Basel (CH)

(72) Inventors:
• Broadhurst, Michael John
Hertfordshire SG8 8HT (GB)
• Hill, Christopher Huw,
Baldock, Hertfordshire SG7 6UT (GB)
• Hurst, David Nigel
Welwyn, Hertfordshire AL6 0DL (GB)

• Jones, Phillip Stephen
Hertfordshire AL8 7PW (GB)
• Kay, Paul Brittain
Baldock Hertfordshire SG7 6RZ, (GB)
• Kilford, Ian Reginald
Hertfordshire AL8 7EE (GB)
• McKinnell, Robert Murray
London W11 2LF (GB)


(74) Representative: Rauber, Beat et al
124 Grenzacherstrasse
4070 Basle (CH)

Remarks:

A request for correction of the claims has been filed pursuant to Rule 88 EPC. A decision on the request will be taken during the proceedings before the Examining Division (Guidelines for Examination in the EPO, A-V, 3.).

(54) **Oxamides as IMPDH inhibitors**

(57) Disclosed are compounds of the general formula



wherein

- R¹ represents heterocyclyl;
R² represents hydrogen, unsubstituted lower alkyl, lower alkoxy, halo, hydroxy or cyano;
R³ represents hydrogen, unsubstituted lower alkyl, lower alkoxy, halo, or cyano;
R⁴ represents hydrogen, lower alkyl, lower cycloalkyl, aryl, or heterocyclyl;

EP 1 127 883 A2

EP 1 127 883 A2

R⁵ represents hydrogen, unsubstituted lower alkyl, lower alkoxy, halo, or cyano;

R⁶ represents hydrogen, unsubstituted lower alkyl, lower alkoxy, halo, or cyano;

R⁷ represents hydrogen, or unsubstituted lower alkyl;

R⁸ represents hydrogen, or unsubstituted lower alkyl;

or R⁴ and R⁸ together with the nitrogen atom to which they are attached represent heterocyclyl; and pharmaceutically acceptable salts thereof. The disclosed oxamide derivatives are inhibitors of the enzyme inosine monophosphate dehydrogenase (IMPDH). They can be used as medicaments, especially for treating immune mediated conditions or diseases, viral diseases, bacterial diseases, parasitic diseases, inflammation, inflammatory diseases, hyperproliferative vascular diseases, tumours, and cancer. They can be used alone, or in combination with other therapeutically active agents, for example, an immunosuppressant, a chemotherapeutic agent, an anti-viral agent, an antibiotic, an antiparasitic agent, an anti-inflammatory agent, an anti-fungal agent and/or an anti-vascular hyperproliferation agent.